XTremedy Medical

An image of Lyn Markey from XTremedy Medical
Logo of XTremedy Medical

Lyn Markey, Xtremedy Medical

Improving infection treatments to prevent unnecessary amputations 

What problem are you solving and what is innovative about your approach?

Deep tissue and bone infections are incredibly difficult to treat requiring multiple surgeries, lengthy hospital stays, and long-term antibiotics. In 20% of patients, an amputation is required to control the infection. Surgical intervention to remove infected tissue is the cornerstone of treatment but surgeons must balance removing infected material whilst preserving healthy tissue required for healing.  

Current treatment modalities either only treat the surface of the wound or use mechanical forces to treat below the surface. Surface treatments fail as they leave infection below the wound bed untreated. Mechanical devices can cause more severe infections by damaging the integrity of the wound bed and propelling the infection deeper. As a result, these treatments are often ineffective, with 50% of patients requiring additional surgeries. 

XTremedy Medical have developed a surgical device that delivers electrical signals through the wound. This device treats both the surface and below to zap any residual infection. The technology is non-thermal and preserves the integrity of the wound during treatment, helping reduce the time required for healing. Patients benefit from reduced surgeries, shortened hospital stays, and antibiotic durations following surgery. 

How is this idea commercially attractive?

With the rise in anti-microbial resistance, infections are becoming more costly and difficult to treat. For diabetic foot ulcers alone, there are over 300,000 procedures each year and a potential market of €600 million (ASP €2,000). This platform technology has scope to expand into the wider chronic wounds, trauma, and surgical site infection markets, with a total potential market of €2.5 billion in the US alone.  

XTremedy Medical have a patent-pending technology with proven anti-microbial properties. This class II device uses technology previously approved by the FDA and there are reimbursement codes available to drive rapid clinical adoption.  Infected wounds are a growing, underserved market, which is ripe for disruption.  

XTremedy Medical was co-founded by Lyn Markey and Camille O’Malley after witnessing the devastation these infections had on patients and surgeons during the BioInnovate Fellowship 2018/19. The team have developed the technology in the TMD lab in NUIG and will spin out in 2022.   

What do you hope to achieve by participating in Big Ideas?

XTremedy Medical are grateful to Enterprise Ireland and for the opportunity to present at Big Ideas. We have just opened our seed funding round and this is an ideal platform to showcase this technology to the investor community.